

United States Patent and Trademark Office

125

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/022,115		12/14/2001	Charles L. Sawyers	30435.53USD2	4057	
20350	7590	03/24/2005	4/2005 E		XAMINER	
		TOWNSEND AT	HAMA, JOANNE			
EIGHTH FL		KO CLIVILK	ART UNIT	PAPER NUMBER		
SAN FRAN	CISCO, C	CA 94111-3834		1632		

DATE MAILED: 03/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		10/022,115	SAWYERS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Joanne Hama, Ph.D.	1632				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠	1) Responsive to communication(s) filed on 06 January 2005.						
2a)⊠	This action is FINAL . 2b) ☐ This	action is non-final.					
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	Disposition of Claims						
5)⊠ 6)⊠ 7)□	·						
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachmen	t(s)						
2) Notic Notic Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa					

Art Unit: 1632

DETAILED ACTION

Applicant's response to the First Action on the Merits filed on January 6, 2005 is acknowledged.

Claims 21-26 have been amended. Claim 35 is newly added.

Claims 21-26, 35 are under consideration.

Withdrawn Objections and Rejections

Claim objections

Claim objections regarding claim dependency to incorrectly numbered claims have been withdrawn. Applicants have amended the claims.

Obviousness-type double patenting

Applicants have filed a terminal disclaimer for U.S. Patent No. 6, 107,540 and U.S. Patent No. 6,365,797, and for patents that may grant with co-pending Applications 10/062,925, and 10/066,266. In view of this, the obviousness type double patenting rejection is withdrawn.

35 U.S.C. § 112, second paragraph

Rejections for claims 21-25 under 35 U.S.C. § 112, second paragraph have been withdrawn.

With regards to claim 21, the Examiner has found the Applicant's argument convincing and withdraws the rejection.

With regards to claim 22, Applicant has amended the claim. The rejection is

withdrawn.

With regards to claims 23-25, Applicant has amended the claim. The rejection is

Page 3

withdrawn.

35 U.S.C. § 102

Rejections for claims 21-23 and 26 are withdrawn. Applicants have provided an

Invention Report that states that the Inventors developed an in vivo prostate cancer

model using SCID mice. Inventors Sawyers, Witte, and Reiter attest that the Invention

was made prior to December 1995, the date of publication of Soff et al.

35 U.S.C. § 103

Rejections for claims 21, 24, 25 are withdrawn. Declaration by the Inventors

antedate the Soff, et al. reference.

Maintained Rejection

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly

claiming the subject matter which the applicant regards as his invention.

Claim 26 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite

for failing to particularly point out and distinctly claim the subject matter which applicant

regards as the invention.

Art Unit: 1632

With regards to claim 26 (i), while Applicant has amended the claim to the Examiner's suggested phrase, claim 26 as instantly pending remains indefinite because the claim lacks an active step.

For purposes of clarity, a change to claim 22 is suggested. As an example, claim 22 may be rewritten as follows:

"The method of claim 21, wherein the determining step comprises comparing the growth of the xenograft in the mouse to the growth of the xenograft in at least one immune deficient mouse provided in step (a) that did not receive the composition or treatment."

Applicants are required to ensure that no new matter is introduced by such an amendment.

Conclusion

Claims 21-25, and 35 are allowed. Claim 26 is not allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joanne Hama, Ph.D. whose telephone number is 571-272-2911. The examiner can normally be reached Monday through Thursday and alternate Fridays from 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image

Application/Control Number: 10/022,115

Art Unit: 1632

problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Page 6

JH

RAM R. SHUKLA, PH.D.